Option Care tapped to provide new HIV therapy

Friday, March 16, 2018

BANNOCKBURN, Ill. – Option Care has been selected by Theratechnologies as an infusion provider for Trogarzo, multidrug resistant human immunodeficiency virus type 1 (HIV-1) infections. Option Care will provide personalized care management support to patients receiving Trogarzo infusions. “Our ability to provide unmatched home and alternate treatment site infusion services allow us to partner with innovators bringing groundbreaking therapies like TrogarzoT to market,” said Matt Deans, vice president, business development at Option Care.